Investor's Business DailyBiogen to Pay Applied Genetic $124 Million to Develop Eye-Disease TreatmentsWall Street JournalBiogen Inc. BIIB -0.32 % will pay Applied Genetic Technologies Corp. AGTC 16.62 % $124 million for license and commercialization rights to several of its gene-based therapies. Shares of AGTC increased by 17% in recent trading. Shares of Biogen were ...UPDATED: Biogen beefs up gene therapy ops with $1B-plus AGTC pactFierceBiotechAlachua-based AGTC announces deal possibly worth more than $1BGainesville SunRoth Capital Positive on Biogen (BIIB), AGTC (ATGC) Collaboration; Reaffirms ...StreetInsider.comMotley Fool -Channel News Asiaall 44 news articles »
Biogen to Pay Applied Genetic $124 Million to Develop Eye
Rating: 4.5
Diposkan Oleh: Unknown
